Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

You are here:  Home >>  News >>  Editors’ Picks >>  The Most Valuable Unsold Assets of the Pharmaceutical Industry in 2017

The Most Valuable Unsold Assets of the Pharmaceutical Industry in 2017

September 11, 2017 By en-cphi.cn

According to data of EvaluatePharma, the top 2 on the following list are Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor, and DBV’s peanut allergy vaccine and Karyopharm’s cancer treatment selinexor also rank in the top 15. While the potential of the two drugs of Kite and Incyte is generally recognized, opinions on other products on the list are likely to be divided.

Equity analysts are not typically known for their prudence when evaluating the R&D work of small drug development companies, therefore, the values (net present value figures) forecast are far less important than the fact that those drugs rank among the following list. In addition, the drugs in development listed in the following list are limited only to the assets owned in major European countries and U.S. companies.

Drug

Company

Today’s NPV (USD 100 million)

NPV as % of market value

Pharmaceutical product type

Main indication

R&D phase

Axicabtagene ciloleucel

Kite Pharma

78.1

111%

Anti-CD19 CAR-T

Non-Hodgkin lymphoma

Filed application

Epacadostat

Incyte

59.8

23%

IDO-1 inhibitor

Melanoma

Phase III

AndexXa

Portola Pharmaceuticals

28.8

91%

Factor Xa inhibitor antidote

Factor Xa inhibitor reversal agent

Filed application

Viaskin Peanut

DBV Technologies

28.6

152%

Peanut allergy vaccine

Peanut allergy

Phase III

Intepirdine

Axovant Sciences

26.4

97%

5-HT6 antagonist

Alzheimer's disease

Phase III

AVXS-101

Avexis

24.8

84%

Gene therapy

Spinal muscular atrophy (SMA)

Phase I

MPC-150-IM

Mesoblast

24.4

422%

Mesenchymal cell therapy

Heart failure

Phase III

LentiGlobin

Bluebird Bio

22.8

52%

Gene therapy

Thalassaemia/sickle cell disease

Phase III

SAGE-547

Sage Therapeutics

20.8

66%

GABA A modulator

Depression, epilepsy

Phase III

Selinexor

Karyopharm Therapeutics

20.7

494%

XPO/CRM 1 inhibitor

Multiple myeloma, diffuse large B-cell lymphoma (DLBCL)

Phase III

NEOD001

Prothena

19.8

89%

Amyloid-beta peptide (Abeta) monoclonal antibody

Amyloidosis

Phase III

LN-144

Iovance Biotherapeutics

17.6

557%

Tumor infiltrating lymphocyte infusion

Melanoma

Phase II

AR101

Aimmune Therapeutics

17.3

173%

Peanut allergy vaccine

Peanut allergy

Phase III

Tipifarnib

Kura Oncology

16.5

937%

Farnesyl transferase inhibitor

Squamous cell cancer of the head and neck (SCCHN)

Phase II

Larotrectinib

Loxo Oncology

16.1

73%

TRK inhibitor

Solid tumors with NTRK-fusion proteins

Phase II

Note: NPV: net present value, data sourced from sales forecast.

1

Most valuable drugs in development

Kite and Incyte’s drugs in development are certainly the most valuable in this evaluation. Axicabtagene ciloleucel is expected to receive approval in the coming weeks, while Incyte is actively deepening cooperation with MSD and Bristol-Myers Squibb (BMS) over epacadostat.

While both drugs in development are technically unpartnered, it seems that either Kite or Incyte has no intention of seeking product licensing deal, however, such deal may be reached if the price is right. In fact, a number of companies have said that they wanted to take the products to market themselves, at least on the U.S. market.

However, for those products in development that will face highly competitive markets, a strong partner is crucial if they are to succeed commercially, such as Axovant’s Alzheimer’s drug intepirdine, Karyopharm’s selinexor for myeloma and lymphomas, or Iovance’s melanoma drug LN-144. It’s worth noting that the NPVs of the selinexor and LN-144 are higher than the market values of their respective companies, suggesting that investors are not as optimistic as sellers.

This disparity is also particularly evident with the U.S. oncology company Kura and Australian biotech company Mesoblast: both need to strive to submit convincing clinical evidence for their major drugs in development. The FDA refused to approve tipifarnib in 2005 when it was owned by J & J, while Mesoblast’s partner in its cell therapy left in 2016. In addition, Avexis’s gene therapy is still in Phase I, with early data release urgently needed.

2

Convincing evidence

For many of such products in development, potential partners would want to see much more convincing data, especially proof of regulatory approval or commercial potential, before considering buying them.

One example is gene therapies, such as, Sage’s epilepsy candidate SAGE-547: this indication is very prone to late-stage failure, and it is very difficult to make predictions according to past situation. Prothena’s amyloidosis project has been ranking on the above list of EvaluatePharma since 2014, however, big pharmaceutical enterprises will presumably continue to overlook this asset worth billions of USD.

However, this does not mean that there are no hopes. Puma’s Nerlynx, and Acadia’s Nuplazid appeared on this list of EvaluatePharma for many years, and they have both been successfully marketed and are forecast to generate strong sales. And, in 2011, an antiviral of U.S. company Pharmasset went on the list, which later become the Sovaldi we know.

But EvaluatePharma had flops in forecasts previous years, like the inhaled insulin Afrezza, Newlink Genetics’ cancer vaccine algenpantucel-L and Biosante’s Libigel. While the absence of a big partner is not necessarily a failure, it would be wise to ask serious questions about these assets’ clinical and commercial values.

By Chu Minhua from Healthcare Executive

Source: Y-LP.com

Readers'Comments
Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53